Literature DB >> 3378852

Penetration of roxithromycin in bronchial secretions.

V De Rose1, A Ferrara, P Mangiarotti, A Nonis, R Bertoletti, G Gialdroni Grassi.   

Abstract

Roxithromycin sputum and serum concentrations after administration of therapeutic doses (150 mg in a single dose) were evaluated in six patients. Blood samples and pooled sputum samples were collected at corresponding time intervals up to 24 h after drug administration. Roxithromycin sputum levels were found to be almost always above serum concentrations, the highest sputum levels being 5.85 +/- 2.5 micrograms/ml in the interval ranging from 2 to 4 h after drug administration. Due to its antibacterial spectrum and favourable pharmacokinetic properties, roxithromycin, like other macrolide antibiotics, seems to be particularly indicated in the treatment of respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3378852

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  4 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

3.  Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice.

Authors:  N C Karalus; J E Garrett; S D Lang; R A Leng; G N Kostalas; R T Cursons; B C Cooper; C J Ryan
Journal:  Infection       Date:  1995       Impact factor: 3.553

Review 4.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.